Inhalation Sciences receives new order worth 1.6 MSEK from major customer in inhalation arena
(Stockholm May 7, 2019) Inhalation Sciences (ISAB) has received an order for a PreciseInhale® system, including the platform's unique integrated inhaler actuator, from an existing customer within the inhalation arena. The order is worth approx. 1.6 million SEK.
PreciseInhale and its range of modules for controlled exposures to aerosols is a comprehensive solution for companies studying inhalation and aerosols in pre-clinical experiments. Of particular interest to the inhaled drug development industry is the system’s ability to generate aerosols from existing and new inhalers. PreciseInhale includes an integrated, software-controlled, automated module that can connect to and generate aerosols from any type of inhaler on the market.
"It’s a sure sign of just how strong our system is when a customer invests in another instrument. This sale is a clear indication that users realize the importance of the PreciseInhale technology we deliver, and that they are willing to expand their investment in it,” says CEO Lena Heffler.
For more information on Inhalation Sciences, please contact:
Lena Heffler, CEO
E-mail: lena.heffler@inhalation.se
Telephone: +46 (0)70 205 9620
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.
The information above was provided by Inhalation Sciences AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on May 7, 2019.
Tags: